1-3 of 3
Nathan G. Dolloff
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

Holly A.F. Stessman, Linda B. Baughn, Aaron Sarver, Tian Xia, Raamesh Deshpande, Aatif Mansoor, Susan A. Walsh, John J. Sunderland, Nathan G. Dolloff, Michael A. Linden, Fenghuang Zhan, Siegfried Janz, Chad L. Myers, Brian G. Van Ness
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 1140–1150.
https://doi.org/10.1158/1535-7163.MCT-12-1151
Published: 09 June 2013
View article titled, Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Open the PDF for Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model in another window
Includes: Supplementary data
Journal Articles

Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9

Nathan G. Dolloff, Joshua E. Allen, David T. Dicker, Nicole Aqui, Dan Vogl, Jozef Malysz, Giampaolo Talamo, Wafik S. El-Deiry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (11): 2321–2330.
https://doi.org/10.1158/1535-7163.MCT-12-0578
Published: 08 November 2012
View article titled, Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9
Open the PDF for Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9 in another window
Includes: Supplementary data
Journal Articles

Abstract C77: Sangivamycin-like molecule 6 (SLM6) exhibits potent and selective anti-multiple myeloma activity through inhibition of P-TEFb.

Nathan G. Dolloff, Giampaolo Talamo, David T. Dicker, Wafik S. El-Deiry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C77.
https://doi.org/10.1158/1535-7163.TARG-11-C77
Published: 12 November 2011
View article titled, Abstract C77: Sangivamycin-like molecule 6 (SLM6) exhibits potent and selective anti-multiple myeloma activity through inhibition of P-TEFb.